CME / ABIM MOC / CE

Immunotherapy in Advanced Non-Small Cell Lung Cancer

Authors: Charu Aggarwal, MD, MPH; Marianne Davies, DNP, ACNP, AOCNP, FAAN; Ticiana Leal, MD; Adam J. Schoenfeld, MD; Lova Sun, MD, MSCE
CME / ABIM MOC / CE Released: 5/3/2024
Valid for credit through: 3/3/2025, 11:59 PM EST

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.00 ABIM MOC points

Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit 

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the management of patients with lung cancer.

The goal of this activity is for learners to be better able to individualize care for patients with advanced NSCLC who are eligible for treatment with immunotherapy as part of the interprofessional team.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data evaluating immunotherapy for patients with advanced NSCLC
Have greater competence related to
- Personalizing treatment decisions for patients with advanced NSCLC eligible for immunotherapy
- Mitigating treatment-related adverse events in patients receiving immunotherapy for advanced NSCLC
Demonstrate greater confidence in their ability to
- Optimize the care of patients with NSCLC and specific mutations as part of the interprofessional team

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Charu Aggarwal, MD, MPH

Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Charu Aggarwal, MD, MPH, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; BeiGene (Beijing) Co., Ltd.; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Genentech; Janssen; Lilly; Merck; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Shionogi & Co., Ltd.; Turning Point Therapeutics
Research funding from: AstraZeneca; Genentech; Incyte Corporation; MacroGenics, Inc.; MedImmune Inc.; Merck Sharp & Dohme GmbH; Roche

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature: Oncology
Yale New Haven Health System
Senior Advanced Practice Provider, Smilow Cancer Hospital
Associate Professor, Yale University School of Nursing
New Haven, Connecticut

Disclosures

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships.

Ticiana Leal, MD

Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Leal and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Leal’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Ticiana Leal, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bristol Myers Squibb Company; Catalyst Pharmaceutical Partners, Inc.; Eisai Co., Ltd.; Genentech; Janssen; Jazz Pharmaceuticals, Inc.; Merck; Novocure; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Takeda
Research funding from: Advaxis, Inc.; Bayer; Pfizer, Inc.
Other: Travel support from Sanofi

Adam J. Schoenfeld, MD

Assistant Attending Physician
Thoracic Oncology Service and Cellular Therapeutics Service
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Disclosures

Adam J. Schoenfeld, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Bristol Myers Squibb Company; Enara Bio; Heat Biologics, Inc; Immunocore Ltd.; Iovance Biotherapeutics; Johnson & Johnson Services, Inc.; KSQ Therapeutics, Inc.; Legend Biotech; Lyell Immunopharma, Inc.; Merck; Perceptive Advisors; Prelude Therapeutics; Oppenheimer and Co. Inc.; Umoja Biopharma
Research funding from: Achilles Therapeutics plc; Bristol Myers Squibb Company; GlaxoSmithKline; Iovance Biotherapeutics; Merck

Lova Sun, MD, MSCE

Assistant Professor of Medicine
Division of Hematology Oncology
Perelman School of Medicine
University of Pennsylvania
Philadephia, Pennsylvania

Disclosures

Lova Sun, MD, MSCE, has the following relevant financial relationships:
Consultant or advisor for: Bayer; Genmab A/S; Regeneron Pharmaceuticals, Inc.; Sanofi; Seagen, Inc.
Research funding from: Blueprint Medicines; Erasca, Inc.; Immunocore; IO Biotech; Seagen, Inc.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-149-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Immunotherapy in Advanced Non-Small Cell Lung Cancer

Authors: Charu Aggarwal, MD, MPH; Marianne Davies, DNP, ACNP, AOCNP, FAAN; Ticiana Leal, MD; Adam J. Schoenfeld, MD; Lova Sun, MD, MSCEFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/3/2024

Valid for credit through: 3/3/2025, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

PD(L)1 +/- Chemo

Dr Ticiana Leal tackles the evolving arena of PD(L)1+/- in this engaging presentation.
Ticiana Leal, MD

Dual Checkpoint Blockade With or Without Chemotherapy

Dual checkpoint blockade and chemotherapy -- are you ready to get caught up on the latest? If so, check out this cutting-edge discussion by Dr Adam Schoenfeld.
Adam J. Schoenfeld, MD

Managing Immune-Related Toxicity: Challenges in NSCLC

This in-depth presentation by Dr Marianne Davis, which addresses the challenges of toxicity in immunotherapy, is not to be missed.
Marianne Davies, DNP, ACNP, AOCNP, FAAN

Practical Applications of Immunotherapy

Get hands-on with this compelling presentation by Dr Lova Sun that highlights practical applications of immunotherapy.
Lova Sun, MD, MSCE

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 7

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Charu Aggarwal, MD, MPH

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Ticiana Leal, MD

Adam J. Schoenfeld, MD

Lova Sun, MD, MSCE

Editor

John Churchwell, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Immunotherapy in Advanced Non-Small Cell Lung Cancer

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Charu Aggarwal, MD, MPH

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Ticiana Leal, MD

Adam J. Schoenfeld, MD

Lova Sun, MD, MSCE

Editor

John Churchwell, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Immunotherapy in Advanced Non-Small Cell Lung Cancer

Contents of This Activity

PD(L)1 +/- Chemo

Dual Checkpoint Blockade With or Without Chemotherapy

Managing Immune-Related Toxicity: Challenges in NSCLC

Practical Applications of Immunotherapy

Learning Feedback Questions